ABCG2 and cancer: Although an FDA-approved ABCG2 inhibitor is currently unavailable, our study demonstrates the potential principle that inhibiting ABCG2 function can restore the efficacy of MTX-211 in ABCG2-overexpressing multidrug-resistant cancer cells.